Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Leslie Tessier"'
Autor:
Witali Aswolinskiy, Enrico Munari, Hugo M. Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W. van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Michelle Stegeman, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H. Lips, Francesco Ciompi
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent need for biomarkers to p
Externí odkaz:
https://doaj.org/article/83850dbe69834722be710c67bd14b3d4
Autor:
Maschenka Balkenhol, Caner Mercan, Leslie Tessier, David Tellez, Roberto Salgado, Heikki Joensuu, Sherene Loi, Stefan Michiels, Denis Larsimont, Anne-Sophie Wegscheider, Axel Niendorf, Mark Sherman, Peter Bult, Francesco Ciompi, Jeroen van der Laak
The discovery of molecular subtypes has corroborated the heterogeneity of breast cancers. But in clinical routine, treatment selection relies on measuring the aggressiveness of the tumor via histopathology, which is routinely based on grading, a prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9179b3a5277903771f62de84ee1dd402
https://doi.org/10.21203/rs.3.rs-2408990/v1
https://doi.org/10.21203/rs.3.rs-2408990/v1
Autor:
Elena Spirina Menand, Manon De Vries-Brilland, Leslie Tessier, Jonathan Dauvé, Mario Campone, Véronique Verrièle, Nisrine J, Jean-Marie Marion, Pierre Chauvet, Christophe Passot, Alain Morel
Ovarian cancer is a complex disease with poor outcome affecting women worldwide. The lack of successful therapeutic options for ovarian cancer patients results in the strong need to identify new biomarkers for patient selection. The development of ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e48776a6faa665d47543309d2f9f807
https://doi.org/10.21203/rs.3.rs-2259784/v1
https://doi.org/10.21203/rs.3.rs-2259784/v1
Autor:
Witali Aswolinskiy, Enrico Munari, Hugo M. Horlings, Lennart Mulder, Giuseppe Bogina, Joyce Sanders, Yat-Hee Liu, Alexandra W. van den Belt-Dusebout, Leslie Tessier, Maschenka Balkenhol, Jeffrey Hoven, Jelle Wesseling, Jeroen van der Laak, Esther H. Lips, Francesco Ciompi
PurposeInvasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy, however, only a fraction of the patients respond to it completely. To prevent over-treating patients with a toxic drug, there is an urgent need for b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b66670c4d8a90b6056b27950460a64e6
https://doi.org/10.1101/2022.11.11.22282205
https://doi.org/10.1101/2022.11.11.22282205